Oruka Therapeutics, Inc. ORKA Payments to Acquire Marketable Securities
Payments to Acquire Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireMarketableSecurities.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s payments to acquire marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s payments to acquire marketable securities?
- Oruka Therapeutics, Inc. (ORKA) reported payments to acquire marketable securities of $90.83M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s payments to acquire marketable securities changed year-over-year?
- Oruka Therapeutics, Inc.'s payments to acquire marketable securities increased by 105.1% year-over-year, from $44.29M to $90.83M.
- What does payments to acquire marketable securities mean?
- Captures the cash used to purchase short-term investments or liquid financial instruments. It reflects the company's strategy for managing excess cash reserves and its approach to treasury management.